market folly

Andrew Spokes' hedge fund firm Farallon Capital has filed a 13G with the SEC regarding shares of DermTech (DMTK).  Per the filing, Farallon now owns 9.8% of DermTech as of August 29th with exposure to over 1.23 million shares. 

Their stake is comprised of 615,385 shares and they also hold "Series A Preferred Shares (as defined in the Preliminary Note) convertible into an aggregate of 615,385 shares."

DermTech shares have been extremely volatile, plummeting from $21.69 in late August to around $5 by the end of the month.

Per Yahoo Finance, DermTech is "a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company sells its products to pathology and oncology practitioners. DermTech, Inc. was incorporated in 1995 and is headquartered in La Jolla, California."